SPOTLIGHT: Portola raises $46M


Portola Pharmaceuticals announced that it has raised $46 million in series B financing that will be used to develop the company's cardiovascular therapies, specifically, moving an oral Factor Xa inhibitor into phase II trials. The round was led by Advanced Technology Ventures (ATV) and Alta Partners. As a result of the financing, Jean George of ATV and Farah Champsi of Alta Partners will be joining the board of directors. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.